“…Another study showed that miRâ4443 promoted Epi resistance in nonâsmallâcell lung cancer by downregulating inositol polyphosphateâ4âphosphatase Type I A and activating Janus kinase 2/signal transducer and activator of transcription 3 pathway (W. Zhang et al, 2018). However, miRâ4443 showed a beneficial effect in ovarian cancer, glioblastoma, osteosarcoma, hepatocellular carcinoma, and colon cancer (Ebrahimi & Reiisi, 2019; Gao et al, 2019; Gong, Wang, Liu, Hu, & Zheng, 2018; Meerson & Yehuda, 2016; C. Zhou et al, 2018). Taking together, miRâ4443 may play different roles in different cancers.…”